|
Infectious Diseases Physician and Head of Travel Medicine and Immigrant Health, Victorian Infectious Diseases Service, the Royal Melbourne Hospital, and Senior Research Fellow, Department of Microbiology and Immunology, University of Melbourne
Peter Doherty Institute, University of Melbourne & Royal Melbourne Hospital, Australia
Email: Steve.Muhi@unimelb.edu.au
VALIDATE Role:
Network Investigator
Research Keywords:
Buruli ulcer
Biography:
Steve’s research focuses on Buruli ulcer. He is currently leading clinical trials in Melbourne, Australia, including testing the novel antibiotic, telacebec, in people with Buruli ulcer, and establishing the world’s first M. ulcerans controlled human infection model (MuCHIM).
Related Websites:
University of Melbourne - Find an Expert Profile
Key Publications:
- Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: consensus statement. MUHI S, Cox V, O'Brien M, Priestley J, Hill J, Murrie A, McDonald A, Callan P, Jenkin G, Friedman N, Singh K, Maggs C, Kelley P, Athan E, Johnson P, O'Brien D. 2025. Medical Journal of Australia. 222(11):571-578. DOI: 10.5694/mja2.52591.
- Mycobacterium ulcerans challenge strain selection for a Buruli ulcer controlled human infection model. MUHI S, Buultjens A, Porter J, Marshall J, Doerflinger M, Pidot S, O'Brien D, Johnson P, Lavender C, Globan M, McCarthy J, Osowicki J, Stinear TP. PLOS Neglected Tropical Diseases. 2024 May 3;18(5):e0011979. DOI: 10.1371/journal.pntd.0011979.
- Perceptions of a Buruli ulcer controlled human infection model: How, who, and why? MUHI S, Schmidt S, Marshall JL, O’Brien DP, Johnson PD, McCarthy JS, Jamrozik E, Osowicki J, Stinear TP. PLOS Neglected Tropical Diseases. 2025 Feb 5;19(2):e0012593. DOI: 10.1371/journal.pntd.0012593.
- A human model of Buruli ulcer: provisional protocol for a Mycobacterium ulcerans controlled human infection study. MUHI S, Marshall JL, O'Brien DP, Johnson PDR, Ross G, Ramakrishnan A, Mackay LK, Doerflinger M, McCarthy JS, Jamrozik E, Osowicki J, Stinear TP. Wellcome Open Research. 2024 Oct 21;9:488. DOI: 10.12688/wellcomeopenres.22719.2.
- A refined low-dose murine model of Mycobacterium ulcerans infection to assess integrated immune networks in Buruli ulcer pathogenesis. MUHI S, Foo IJH, Kedzierski L, Porter JL, McQuilten HA, Howden B, Kedzierska K, Buultjens AH, Chua BY, Stinear TP. BioRxiv. DOI: 10.1101/2025.04.23.650345.
- A Mycobacterium ulcerans vaccine pilot trial using an accurate low-dose challenge. MUHI S, Porter JL, Stinear TP. Microbiology Spectrum. 2024 Aug 6;12(8):e00555-24. DOI: 10.1128/spectrum.00555-24.
- Systematic review of M. bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis. MUHI S, Stinear TP. Vaccine. 2021 Dec 8;39(50):7238-52. DOI: 10.1016/j.vaccine.2021.05.092.
- Experimental infection of ringtail possums (Pseudocheirus peregrinus) with Mycobacterium ulcerans, the agent of Buruli ulcer. Blasdell KR, Ploeg RJ, Hobbs EC, MUHI S, Riddell SJ, Cunneen A, Kelly ML, Maynard K, Malcolm TR, Islam MT, Boyd V, Stinear TP, Pidot SJ, Athan E, O'Brien DP. Scientific Reports. 2024 Oct 25;14(1):25352. DOI: 10.1038/s41598-024-76857-1.
|
